Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

Oragenics (NYSE American: OGEN) announced its participation at the Emergencies in Medicine Conference, where Chief Medical Officer Dr. James Kelly pr ...

The Walk to Defeat ALS fundraiser is marking 25 years of walking events across the U.S. in support of ALS patients and their ...

Oragenics (OGEN) announced its participation at the Emergencies in Medicine Conference, where Dr. James Kelly, Chief Medical Officer and ...

Long COVID is a complex and often debilitating complication following COVID-19 infection. It affects millions worldwide, presenting with symptoms such as persistent fatigue, cognitive impairment ...

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and ...

Tiziana Life Sciences ( ($TLSA) ) has shared an update. On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a ...

NEW YORK, Feb. 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hum ...

H1N1 Vaccines Market H1N1 Vaccines Market Dublin, Feb. 25, 2025 (GLOBE NEWSWIRE) -- The "H1N1 Vaccines Market Analysis by ...

A farm’s battle with pneumonia in young cattle uncovered shocking financial losses. See why vaccination is key to protecting performance ...

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, “Partnering with Renaissance is a significant milestone in our mission ...

NEW YORK, Feb. 21, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hum ...